LPX Lipoxen

 

TIDMLPX 
 
RNS Number : 0833A 
Lipoxen PLC 
01 October 2009 
 

Lipoxen PLC 
("Lipoxen" or "the Company") 
 
 
Additional listing and Total Voting Right 
 
 
London, UK, 1 October 2009 - Lipoxen PLC (AIM:LPX) a bio-pharmaceutical company 
specialising in the development of high value differentiated biologicals, 
vaccines and siRNA delivery, announces that application has been made to AIM, a 
market of the London Stock Exchange plc, for the admission of 100,000 ordinary 
shares of 0.5p each (the "New Ordinary Shares"). 
 
 
The New Ordinary Shares are being admitted pursuant to the exercise of options 
under the Lipoxen Plc Unapproved Share Option Plan. 
 
 
It is expected that dealings in the New Ordinary Shares, which will rank pari 
passu in all respects with the existing issued share capital of the Company, 
will commence on 2 October 2009. 
 
 
In conformity with the FSA's Disclosure and Transparency Rules, the Company 
notifies the market of the following: 
 
 
Following the admission to trading on AIM of the Ordinary Shares mentioned above 
Lipoxen's capital consists of 154,210,085 ordinary shares of 0.5p each 
("Ordinary Shares") with voting rights. No Ordinary Shares are held in treasury, 
therefore the total number of voting rights in the Company is 154,210,085. 
 
 
The above figure (154,210,085) may be used by shareholders as the 
denominator for the calculations by which they will determine if they are 
required to notify their interest in, or a change to their interest in, Lipoxen 
under the FSA's Disclosure and Transparency Rules. 
 
 
Enquiries 
+-------------------------------------------------+-------------------------+ 
| Lipoxen plc                                     |    +44 (0)20 7691 3583  | 
+-------------------------------------------------+-------------------------+ 
| M. Scott Maguire, Chief Executive Officer       |                         | 
+-------------------------------------------------+-------------------------+ 
|                                                 |                         | 
+-------------------------------------------------+-------------------------+ 
| Singer Capital Markets (nominated adviser)      |     +44 (0)20 3205 7500 | 
+-------------------------------------------------+-------------------------+ 
| Jeff Keating / Claes Spång                      |                         | 
+-------------------------------------------------+-------------------------+ 
|                                                 |                         | 
+-------------------------------------------------+-------------------------+ 
| Noble & Company                                 |   +44 (0) 20 7763 2200  | 
+-------------------------------------------------+-------------------------+ 
| John Llewellyn-Lloyd / Sam Reynolds             |                         | 
+-------------------------------------------------+-------------------------+ 
|                                                 |                         | 
+-------------------------------------------------+-------------------------+ 
| Buchanan Communications                         |     +44 (0)20 7466 5000 | 
+-------------------------------------------------+-------------------------+ 
| Mary-Jane Elliott, Lisa Baderoon, Rebecca Skye  |                         | 
| Dietrich, Catherine Breen                       |                         | 
+-------------------------------------------------+-------------------------+ 
 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 IOEBSBDGRGGGGCB 
 

Lipoxen (LSE:LPX)
Historical Stock Chart
From Jun 2024 to Jul 2024

Lipoxen (LSE:LPX)
Historical Stock Chart
From Jul 2023 to Jul 2024